top of page
CTD-ILD Multidisciplinary considerations

After attending this event, participants will be better able to;

  1. Identify CTD-ILD, its risk factors, and immunomodulation considerations;

  2. Articulate the clinical relevance of identifying progressive pulmonary fibrosis in CTD-ILD; 

  3. Apply when to use anti-fibrotic therapies in patients with CTD-ILD;

  4. Recognize multidisciplinary roles in the management of CTD-ILD. 

Please note, only the live webinar event was accredited.
Viewing the recording without attending live is not eligible for MOC Section 1 Credits. 


Nathan Hambly, MD, FRCPC
Associate Professor, Department of Medicine, McMaster University
Interstitial Lung Disease Program Director
Clinical Lead Firestone Institute Pulmo
nary Hypertension Program
Hamilton, ON

Mohammed Osman, MD, PhD, FRCPC
Clinician Scientist, Assistant Professor
Consultant Rheumatologist and Clinical Immunologist
Director of systemic sclerosis (SSc) and Microvascular Clinics
Department of Medicine, University of Alberta

MODERATOR - Maggie Larché, MBChB, MRCP (UK), PhD
Professor, Department of Medicine, McMaster University
Director, Canadian Scleroderma Research Group
Hamilton, ON

Hambly B&W.png
Osman B&W.jpg

This initiative has been sponsored in part by Boehringer Ingelheim through an educational grant.

bottom of page